Berlex Bonefos meeting cancelled
Executive Summary
FDA has cancelled the Dec. 2 meeting of FDA's Oncologic Drugs Advisory Committee that was to look at Berlex' Bonefos for breast cancer bone metastases. It is the second time an advisory committee has been cancelled for Bonefos; in December 2001 an advisory committee meeting was cancelled to allow then-NDA holder Anthra Pharmaceuticals more time to respond to issues raised by FDA. The committee will still review Ilex/Enzon' liposomal vincristine formulation Marqibo and Ilex' Clolar (clofarabine) on Dec. 1 (1"The Pink Sheet" Oct. 11, 2004, In Brief). [Editor's Note: To 2watch a webcastor order a video/DVD of this meeting, visit FDAAdvisoryCommittee.com.]...